Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have earned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $15.17.

A number of analysts have commented on the company. Morgan Stanley lowered their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. UBS Group cut their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Finally, Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th.

Insider Activity

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the purchase, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.57% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC raised its holdings in Elanco Animal Health by 28.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock valued at $124,000 after acquiring an additional 2,264 shares during the last quarter. DDD Partners LLC acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $5,974,000. Geode Capital Management LLC lifted its position in Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after buying an additional 65,303 shares in the last quarter. Atom Investors LP boosted its stake in Elanco Animal Health by 310.3% during the third quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after buying an additional 261,559 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its holdings in Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after buying an additional 209,734 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 1.7 %

NYSE:ELAN opened at $10.51 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a 50-day moving average of $11.32 and a 200 day moving average of $12.51. Elanco Animal Health has a 1-year low of $10.03 and a 1-year high of $18.80. The firm has a market cap of $5.20 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the business earned $0.08 earnings per share. Elanco Animal Health’s revenue was down 1.4% on a year-over-year basis. As a group, research analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.